240 related articles for article (PubMed ID: 32539877)
21. Oral Vancomycin for Secondary Prophylaxis of Clostridium difficile Infection.
Brown CC; Manis MM; Bohm NM; Curry SR
Ann Pharmacother; 2019 Apr; 53(4):396-401. PubMed ID: 30450942
[TBL] [Abstract][Full Text] [Related]
22. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients.
Splinter LE; Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson GE; Saddler CM; Smith JA; Safdar N; Redfield RR
Ann Pharmacother; 2018 Feb; 52(2):113-119. PubMed ID: 28844154
[TBL] [Abstract][Full Text] [Related]
23. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
24. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
Kimura T; Stanhope S; Sugitani T
J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
[TBL] [Abstract][Full Text] [Related]
25. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.
Haeusler GM; Lehrnbecher T; Agyeman PKA; Loves R; Castagnola E; Groll AH; van de Wetering M; Aftandilian CC; Phillips B; Chirra KM; Schneider C; Dupuis LL; Sung L
Eur J Cancer; 2022 Aug; 171():1-9. PubMed ID: 35696884
[TBL] [Abstract][Full Text] [Related]
26. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
27. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.
Wombwell E; Patterson ME; Bransteitter B; Gillen LR
Clin Infect Dis; 2021 Nov; 73(9):e2512-e2518. PubMed ID: 32575126
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.
Novosad SA; Mu Y; Winston LG; Johnston H; Basiliere E; Olson DM; Farley MM; Revis A; Wilson L; Perlmutter R; Holzbauer SM; Whitten T; Phipps EC; Dumyati GK; Beldavs ZG; Ocampo VLS; Davis CM; Kainer M; Gerding DN; Guh AY
J Gen Intern Med; 2020 Feb; 35(2):412-419. PubMed ID: 31768906
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for recurrent
Baldassarre L; Quach-Thanh C; Mouajou Feujio V; Tadount F; Deyirmendjian C; Lefebvre MA; Thampi N; Schneider O; Fabri-Karam I; O'Donnell S; Okeny-Owere J; Audy N; Desmarais N
Infect Control Hosp Epidemiol; 2024 Feb; 45(2):182-187. PubMed ID: 37700539
[TBL] [Abstract][Full Text] [Related]
32. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
33. Impact of Clostridioides difficile length of treatment on rates of recurrence in patients on concurrent antibiotics.
Rajakumar I; Jaber R; Ali R; Rennert-May E; Sabuda D
Am J Infect Control; 2023 Nov; 51(11):1213-1217. PubMed ID: 37105356
[TBL] [Abstract][Full Text] [Related]
34. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735
[TBL] [Abstract][Full Text] [Related]
35. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent
Chang LL; Allegretti J; Skinner AM; Dubberke ER
N Engl J Med; 2023 Feb; 388(7):654-656. PubMed ID: 36791167
[No Abstract] [Full Text] [Related]
36. [THE EPIDEMIOLOGY OF CLOSTRIDIUM DIFFICILE INFECTIONS AND ASPECTS PERTAINING TO TREATMENT WITH VANCOMYCIN AT ASSAF HAROFEH MEDICAL CENTER].
Youngster I; Lazarovitch T; Bondorenco M; Kachlon Y; Toledano L; Mengesha B; Zaidenstein R; Daniel C; Dadon M; Marchaim D
Harefuah; 2018 May; 157(5):305-308. PubMed ID: 29804335
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
38. A Multicenter Evaluation of Probiotic Use for the Primary Prevention of Clostridioides difficile Infection.
Heil EL; Harris AD; Brown C; Seung H; Thom KA; von Rosenvinge E; Sorongon S; Pineles L; Goodman KE; Leekha S
Clin Infect Dis; 2021 Oct; 73(8):1330-1337. PubMed ID: 33972996
[TBL] [Abstract][Full Text] [Related]
39. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
[TBL] [Abstract][Full Text] [Related]
40. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection.
Sehgal K; Zandvakili I; Tariq R; Pardi DS; Khanna S
Expert Rev Anti Infect Ther; 2022 Apr; 20(4):577-583. PubMed ID: 34693838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
